Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Therapeutic Morass

被引：3

作者：

Gryaznov, Anton A. ^{[1
,2
]}

Saeyeldin, Ayman ^{[1
]}

Abdelbaky, Mohamed ^{[1
]}

Zafar, Mohammad A. ^{[1
]}

Tanweer, Maryam ^{[1
]}

Imran, Mahnoor ^{[1
]}

Papanikolaou, Dimitra ^{[1
]}

Erben, Young ^{[1
]}

Zefirova, Julia ^{[3
]}

Ziganshin, Bulat A. ^{[1
,4
]}

Elefteriades, John A. ^{[1
]}

机构：

[1] Yale Univ, Aort Inst, Yale New Haven Hosp, Sch Med, 789 Howard Ave,Clin Bldg CB317, New Haven, CT 06519 USA

[2] St Marys Hosp, Dept Surg, Waterbury, CT USA

[3] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA

[4] Kazan State Med Univ, Dept Surg Dis 2, Kazan, Russia

来源：

CARDIOLOGY | 2018年 / 140卷 / 04期

关键词：

Anticoagulation; Adverse effects; Aortic valve replacement; Bioprosthesis; Mechanical aortic valve; Complications; LONG-TERM DURABILITY; HEART-VALVE; THROMBOEMBOLIC COMPLICATIONS; EARLY ANTICOAGULATION; ORAL ANTICOAGULATION; COMPARING WARFARIN; OUTCOMES; TRANSCATHETER; IMPLANTATION; SOCIETY;

D O I：

10.1159/000490924

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Valvular heart disease is a common pathologic condition that affects 6 million people in the United States and more than 100 million worldwide. The most common valvular disorder is aortic stenosis. Current American and European guidelines recommend surgical management for symptomatic aortic stenosis with low risk of perioperative complications and endovascular intervention for high-risk patients with multiple comorbidities. Considering the increasing volume of aortic valve replacement (AVR) with biological valves, it is very important to select the appropriate anticoagulant after surgical AVR. In this article, we review the impact of anticoagulation on immediate and remote complications after AVR. (C) 2018 S. Karger AG, Basel

引用

页码：213 / 221

页数：9

共 50 条

[1] [Anonymous], NAT REV CARDIOL
[2] [Anonymous], SEMIN THORAC CARDIOV
[3] [Anonymous], J INTERV CARDIOL
[4] Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac):: prospective, randomized, co-operative trial
Aramendi, JI
Mestres, CA
Martinez-León, J
Campos, V
Muñoz, G
Navas, C
[J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 27 (05) : 854 - 860
[5] Aramendi JL, 1998, J HEART VALVE DIS, V7, P610
[6] Noninferiority of Closely Monitored Mechanical Valves to Bioprostheses Overshadowed by Early Mortality Benefit in Younger Patients
Badhwar, Vinay
Ofenloch, John C.
Rovin, Joshua D.
van Gelder, Hugh M.
Jacobs, Jeffrey P.
[J]. ANNALS OF THORACIC SURGERY, 2012, 93 (03) : 748 - 753
[7] Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis
Banbury, MK
Cosgrove, DM
White, JA
Blackstone, EH
Frater, RWM
Okies, JE
[J]. ANNALS OF THORACIC SURGERY, 2001, 72 (03) : 753 - 757
[8] EACTS Guide on Valvulopathy Treatment
Baumgartner, Helmut
Falk, Volkmar
Bax, Jeroen J.
De Bonis, Michele
Hamm, Christian
Holm, Per Johan
Lung, Bernard
Lancellotti, Patrizio
Lansac, Emmanuel
Rodriguez Munoz, Daniel
Rosenhek, Raphael
Sjogren, Johan
Mas, Pilar Tornos
Vahanian, Alec
Walther, Thomas
Wendler, Olaf
Windecker, Stephan
Luis Zamorano, Jose
[J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (02): : 110 - 110
[9] THE RISK OF THROMBOEMBOLIC COMPLICATIONS WITHOUT ANTICOAGULATION AFTER SURGICAL AORTIC VALVE REPLACEMENT WITH A BIOPROSTHESIS
Berger, Peter B.
Vedamurthy, Deepak
Casale, Alfred
Sun, Haiyan
Benoit, Charles
Ferrari, Ashley
Trocciola, Susan
Sayed, Ibrahim Ismail
Carter, Russell
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A2041 - A2041
[10] BLAIR KL, 1994, CIRCULATION, V90, P214

← 1 2 3 4 5 →